← Back to Search

Brain Stimulation

Accelerated TBS for Suicidality

N/A
Waitlist Available
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have not received single-pulse or repetitive-TMS in the past, i.e. considered "TMS naïve".
Inpatients admitted for "suicidality" with a documented diagnosis of MDD
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to final visit
Awards & highlights

Study Summary

This trial will test whether a continuous, accelerated form of transcranial magnetic stimulation (TMS) can help inpatients with suicidal ideation. 40 subjects will be recruited and randomly assigned to either the active or sham TMS group. Subjects will complete mood surveys throughout the trial, which will last 7-10 days.

Who is the study for?
This trial is for inpatients aged 18-65 with major depressive disorder (MDD) and current suicidal thoughts, who have never had TMS treatment before. They must pass a safety questionnaire to participate. People with borderline personality disorder, past brain stimulation treatments, schizophrenia spectrum disorders, epilepsy or other major neurological issues can't join.Check my eligibility
What is being tested?
The study tests accelerated Thetaburst stimulation (a type of Transcranial magnetic stimulation) on patients with suicidality. Participants are randomly assigned to either real TMS or a sham (fake) treatment over 7-10 days and will complete mood surveys to track changes.See study design
What are the potential side effects?
While the document doesn't list specific side effects, typical ones from TMS may include headache, scalp discomfort at the site of stimulation, tingling or spasms in facial muscles.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never undergone TMS treatment.
Select...
I am hospitalized for suicidal thoughts and have been diagnosed with major depressive disorder.
Select...
I am between 18 and 65 years old.
Select...
I have never undergone TMS therapy before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to final visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to final visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Inventory of Depressive Symptom (Self-report)
Change in Suicidal Ideation Attributes Scales (SI-DAS)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active acTBSActive Control1 Intervention
For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT. Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays.
Group II: ShamPlacebo Group1 Intervention
All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,528 Previous Clinical Trials
10,276,811 Total Patients Enrolled

Media Library

accelerated Thetaburst stimulation (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04197765 — N/A
Suicidality Research Study Groups: Active acTBS, Sham
Suicidality Clinical Trial 2023: accelerated Thetaburst stimulation Highlights & Side Effects. Trial Name: NCT04197765 — N/A
accelerated Thetaburst stimulation (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04197765 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are the researchers still recruiting participants for this experiment?

"Unfortunately, according to the clinicaltrials.gov database, this particular study is no longer accepting applications as of November 9th 2021 having initially been posted on January 1st 2020. Nevertheless, there are still 101 alternative trials actively recruiting patients at present."

Answered by AI

Who can enroll in this research study?

"This clinical trial requires that those seeking to participate should have suicidal ideations and fall between 18-65 years old. Altogether, 40 individuals will be admitted into the study."

Answered by AI

Are individuals aged 35 and older eligible to participate in the experiment?

"The eligibility criteria for this clinical trial requires that participants be aged 18 or older and 65 or younger."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
Resnick Neuropsychiatric Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
acTBS Treatment for Inpatient Subjects With Suicidality
Andrew F. Leuchter 2020. "acTBS Treatment for Inpatient Subjects With Suicidality". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04197765.
All > Tb
~5 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top